Effects of Triazole Antifungal Agents on the Plasma Concentration and Dosage of Cyclosporin in Patients with Aplastic Anaemia

Table 2

Effect of POS or FCZ on C/D ratio of CsA in aplastic anaemia patients.

Time	FCZ group			POS group
	C (ng/mL)	C/D		C (ng/mL)	C/D
		(ng/mL)/(mg/d)			(ng/mL)/(mg/d)
Without azole co-medication	105.91 ± 56.91	0.54 ± 0.34		152.77 ± 55.67	0.75 ± 0.25
With azole co-medication	186.35 ± 66.66	0.95 ± 0.48	<0.001^a	274.18 ± 163.96	1.48 ± 0.73	0.038^a
With azole co-medication (1∼7 d)	159.10 ± 88.84	0.77 ± 0.37	0.007^b	252.1 ± 160.22	1.30 ± 0.58	0.037^b
With azole co-medication (8∼21 d)	189.12 ± 68.60	0.95 ± 0.54	0.005^c	293.47 ± 147.78	1.87 ± 1.15	0.006^c

^a values for comparisons between with azole co-medication (total) and without azole co-medication. ^b values for comparisons between with azole co-medication (1–7 d) and without azole co-medication. ^c values for comparisons between with azole co-medication (8–21 d) and without azole co-medication.